Back to top

Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?

Read MoreHide Full Article

Investors focused on the Medical space have likely heard of Eli Lilly and (LLY - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

Eli Lilly and is one of 818 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. LLY is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for LLY's full-year earnings has moved 6.14% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

Based on the latest available data, LLY has gained about 27.76% so far this year. Meanwhile, the Medical sector has returned an average of 2.71% on a year-to-date basis. This means that Eli Lilly and is outperforming the sector as a whole this year.

Looking more specifically, LLY belongs to the Large Cap Pharmaceuticals industry, which includes 14 individual stocks and currently sits at #17 in the Zacks Industry Rank. Stocks in this group have gained about 5.35% so far this year, so LLY is performing better this group in terms of year-to-date returns.

Going forward, investors interested in Medical stocks should continue to pay close attention to LLY as it looks to continue its solid performance.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Eli Lilly and Company (LLY) - free report >>

More from Zacks Tale of the Tape

You May Like

Published in